Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at StockNews.com

StockNews.com upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a sell rating to a hold rating in a research note released on Thursday.

A number of other analysts have also recently commented on the stock. Wells Fargo & Company dropped their price target on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating on the stock in a research note on Wednesday. Bank of America increased their price objective on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a buy rating in a report on Wednesday. The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a buy rating in a report on Tuesday, August 13th. JPMorgan Chase & Co. decreased their price target on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating on the stock in a report on Wednesday. Finally, Stifel Nicolaus started coverage on shares of Ascendis Pharma A/S in a research note on Friday, May 31st. They issued a buy rating and a $200.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $187.08.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $119.15 on Thursday. The business has a fifty day simple moving average of $134.38 and a two-hundred day simple moving average of $138.07. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00. The company has a market capitalization of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Private Ocean LLC bought a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at about $36,000. GAMMA Investing LLC lifted its position in Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 102 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period. Finally, Bessemer Group Inc. grew its holdings in shares of Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.